6-Mercaptopurine Metabolism in Crohn's Disease: Correlation with Efficacy and Toxicity

Overview

Journal Gut

Specialty Gastroenterology

Date 1996 Sep 1

PMID 8949645

Citations 66

Authors

C Cuffari

Y Theoret

S Latour

G SEIDMAN

Affiliations

Soon will be listed here.

Abstract

Background: 6-Mercaptopurine (6-MP) has confirmed short and longterm efficacy in the treatment of IBD. However, the relation between its metabolism, efficacy, and side effects is not well understood.

Aims: To assay 6-MP metabolites and to correlate levels with drug compliance, disease activity, and adverse effects of treatment.

Patients: Heparinised blood was obtained prior to daily administration of 6-MP in 25 adolescent Crohn's disease patients (14 ileocolitis, 11 colitis) receiving 1.2 (range 0.4-1.6) mg/kg/day for a mean of 17 (range 4-65) months.

Methods: Erythrocyte free bases 6-thioguanine (6-TG) and 6-methyl-mercaptopurine (6-MMP) were measured (pmol/8 x 10(8) red blood cells) using reverse phase high performance liquid chromatography.

Results: Disease activity (modified Harvey-Bradshaw index) improved significantly with 6-MP (p = 0.001). Clinical remission was achieved in 72% of patients, who stopped taking prednisone, or were successfully weaned to a low alternate day dose (< 0.4 mg/kg/OD). Remission correlated well with erythrocyte 6-TG (p < 0.05), but not 6-MMP levels. Neutropenia was associated with 6-MP use (p < 0.005), but did not correlate with erythrocyte 6-MP metabolite levels. One patient refractory to 6-MP had 6-TG, but no measureable 6-MMP production, suggesting deficient thiopurine methyl-transferase activity or poor compliance. 6-MP induced complications (hepatitis, pancreatitis, and marrow suppression) were generally associated with increased 6-MMP levels.

Conclusions: These results suggest that high performance liquid chromatography measurement of erythrocyte 6-MP metabolites may provide a quantitative assessment of patient responsiveness and compliance to treatment. The data support an immunosuppressive role for 6-TG, and potential cytotoxicity of raised 6-MMP levels.

Citing Articles

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS).

Zhang L, Mao W, Liu D, Hu B, Lin X, Ran J Front Pharmacol. 2023; 14:1231320.

PMID: 38044938 PMC: 10690789. DOI: 10.3389/fphar.2023.1231320.

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines.

Looser R, Doulberis M, Rossel J, Franc Y, Muller D, Biedermann L Ann Gastroenterol. 2023; 36(6):637-645.

PMID: 38023976 PMC: 10662061. DOI: 10.20524/aog.2023.0832.

Pancreatic Involvement in the Course of Inflammatory Bowel Disease in Children-A Multi-Center Study.

Daniluk U, Krawiec P, Pac-Kozuchowska E, Dembinski L, Bukowski J, Banaszkiewicz A J Clin Med. 2023; 12(13).

PMID: 37445210 PMC: 10342734. DOI: 10.3390/jcm12134174.

Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial.

Lowenberg M, Volkers A, van Gennep S, Mookhoek A, Montazeri N, Clasquin E J Crohns Colitis. 2023; 17(7):1055-1065.

PMID: 36847130 PMC: 10394500. DOI: 10.1093/ecco-jcc/jjad022.

A review of the therapeutic management of Crohn's disease.

Kumar A, Cole A, Segal J, Smith P, Limdi J Therap Adv Gastroenterol. 2022; 15:17562848221078456.

PMID: 35198041 PMC: 8859667. DOI: 10.1177/17562848221078456.

References

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

Harvey R, Bradshaw J . A simple index of Crohn's-disease activity. Lancet. 1980; 1(8167):514. DOI: 10.1016/s0140-6736(80)92767-1. View

Szumlanski C, Weinshilboum R . Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995; 39(4):456-9. PMC: 1365137. DOI: 10.1111/j.1365-2125.1995.tb04478.x. View

Zimm S, Collins J, Riccardi R, ONeill D, Narang P, Chabner B . Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med. 1983; 308(17):1005-9. DOI: 10.1056/NEJM198304283081705. View

Lennard L, Rees C, Lilleyman J, Maddocks J . Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983; 16(4):359-63. PMC: 1428034. DOI: 10.1111/j.1365-2125.1983.tb02178.x. View

Brogan M, Hiserodt J, Oliver M, Stevens R, Korelitz B, Targan S . The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol. 1985; 5(3):204-11. DOI: 10.1007/BF00915512. View

Belli D, Seidman E, Bouthillier L, Weber A, Roy C, Pletincx M . Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988; 94(3):603-10. DOI: 10.1016/0016-5085(88)90230-2. View

Lennard L, VAN LOON J, Weinshilboum R . Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989; 46(2):149-54. DOI: 10.1038/clpt.1989.119. View

Present D, Meltzer S, Krumholz M, Wolke A, Korelitz B . 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111(8):641-9. DOI: 10.7326/0003-4819-111-8-641. View

10.

Lennard L, Lilleyman J . Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989; 7(12):1816-23. DOI: 10.1200/JCO.1989.7.12.1816. View

11.

Markowitz J, Rosa J, Grancher K, Aiges H, Daum F . Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 1990; 99(5):1347-51. DOI: 10.1016/0016-5085(90)91160-8. View

12.

Verhave M, Winter H, Grand R . Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990; 117(5):809-14. DOI: 10.1016/s0022-3476(05)83349-9. View

13.

Perrault J, Greseth J, Tremaine W . 6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clin Proc. 1991; 66(5):480-4. DOI: 10.1016/s0025-6196(12)62388-x. View

14.

OBrien J, Bayless T, Bayless J . Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991; 101(1):39-46. DOI: 10.1016/0016-5085(91)90457-v. View

15.

Markowitz J, Daum F, Cohen S, Glassman M, Holmes R, Piccoli D . Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. J Pediatr Gastroenterol Nutr. 1991; 12(4):411-23. View

16.

Lennard L . The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43(4):329-39. DOI: 10.1007/BF02220605. View

17.

Markowitz J, Grancher K, Mandel F, Daum F . Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol. 1993; 88(1):44-8. View

18.

Bostrom B, Erdmann G . Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1993; 15(1):80-6. View

19.

Bokkerink J, Stet E, De Abreu R, Damen F, Hulscher T, Bakker M . 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol. 1993; 45(7):1455-63. DOI: 10.1016/0006-2952(93)90045-x. View

20.

Ewe K, Press A, Singe C, Stufler M, Ueberschaer B, Hommel G . Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993; 105(2):367-72. DOI: 10.1016/0016-5085(93)90709-l. View